Babaluke的个人主页 - 老虎社区

Babaluke

Babaluke

暂无个人介绍

IP属地：未知

0关注

0粉丝

0主题

0勋章

2021-06-23

Great ariticle, would you like to share it?

@小虎活动:【老虎7周年】集卡瓜分百万奖金

2021-06-23

Ok

抱歉，原内容已删除

2021-06-23

Ok

EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote>

2021-06-23

What

EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote>

2021-06-23

Yums

Krispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转向线上，Krispy Kreme寻求6.4亿美元IPO</blockquote>

2021-06-23

Ok

抱歉，原内容已删除

2021-06-23

Cool

抱歉，原内容已删除

2021-06-23

Good

抱歉，原内容已删除

2021-06-23

Good

FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管一些员工表示担忧，FDA还是批准了百健(Biogen)的阿尔茨海默病药物</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3584774162933077","uuid":"3584774162933077","gmtCreate":1621680138843,"gmtModify":1624441399370,"name":"Babaluke","pinyin":"babaluke","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":123566429,"gmtCreate":1624429967061,"gmtModify":1634006224487,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123566429","repostId":"114899451","repostType":1,"repost":{"id":114899451,"gmtCreate":1623063308869,"gmtModify":1631884627596,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"36984908995200","idStr":"36984908995200"},"themes":[],"title":"【老虎7周年】集卡瓜分百万奖金","htmlText":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可参与活动</a> &#x1;如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。&#x1;如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 &#x1; &#x1;如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。&#x1; 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP &gt; 我的 &gt; 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","listText":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可参与活动</a> &#x1;如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。&#x1;如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 &#x1; &#x1;如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。&#x1; 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP &gt; 我的 &gt; 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","text":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ 戳我即可参与活动 \u0001如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。\u0001如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 \u0001 \u0001如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。\u0001 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP > 我的 > 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","images":[{"img":"https://static.tigerbbs.com/ab28db31a19b458d604a8bf02becddd3","width":"415","height":"125"},{"img":"https://static.tigerbbs.com/5227ebb594fe55b532c840acef147d7b","width":"415","height":"495"},{"img":"https://static.tigerbbs.com/92e88357b534f504b3088bc22f577a83","width":"415","height":"326"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114899451","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":8,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123518556,"gmtCreate":1624429005975,"gmtModify":1634006232788,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123518556","repostId":"2145671770","repostType":2,"isVote":1,"tweetType":1,"viewCount":3241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123510136,"gmtCreate":1624428873625,"gmtModify":1634006234187,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123510136","repostId":"1123710128","repostType":4,"repost":{"id":"1123710128","kind":"news","pubTimestamp":1624406277,"share":"https://www.laohu8.com/m/news/1123710128?lang=zh_CN&edition=full","pubTime":"2021-06-23 07:57","market":"us","language":"en","title":"EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1123710128","media":"Bloomberg","summary":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than prev","content":"<p>(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.</p><p><blockquote>（彭博社）——根据一项新的研究，随着更严格的法规和不断上升的兴趣推动了对零排放交通的需求，全球电动汽车将在2033年到来，比之前的预期提前了五年。</blockquote></p><p> Consultant Ernst &amp; Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.</p><p><blockquote>咨询公司安永会计师事务所(Ernst&amp;Young LLP)目前预计，在全球最大的汽车市场欧洲、中国和美国，电动汽车销量将在12年内超过化石燃料燃烧器。安永使用人工智能预测工具预测，到2045年，非电动汽车销量预计将骤降至全球汽车市场的1%以下。</blockquote></p><p> Strict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.</p><p><blockquote>政府应对气候变化的严格要求正在推动欧洲和中国的需求，在这些国家，汽车制造商和消费者因销售和购买传统汽油和柴油汽车而面临越来越多的经济处罚。安永预计欧洲将引领电动化潮流，到2028年，零排放车型的销量将超过所有其他推进系统。安永预测，这一临界点将于2033年在中国到来，2036年在美国到来。</blockquote></p><p> The U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.</p><p><blockquote>美国落后于世界其他主要市场，因为唐纳德·特朗普总统执政期间放松了燃油经济性法规。自1月份上任以来，乔·拜登总统重新加入了巴黎气候协议，并提议斥资1740亿美元加速向电动汽车的转变，包括在全国安装50万个充电站。</blockquote></p><p> “The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”</p><p><blockquote>安永全球先进制造和移动出行负责人兰迪·米勒在接受采访时表示：“我们认为拜登政府的监管环境是一个很大的贡献者，因为他有雄心勃勃的目标。”“这种对美洲的影响将产生增压效应。”</blockquote></p><p> There also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.</p><p><blockquote>消费者对电动汽车的需求也在不断增长，从特斯拉公司热销的Model 3到传统汽车制造商的新型电动车型，例如通用汽车公司的电池驱动悍马卡车和福特汽车公司的F-150闪电皮卡。据咨询公司AlixPartners称，目前全球汽车制造商对电池驱动车型的投资超过2300亿美元。</blockquote></p><p> ‘More Appealing’</p><p><blockquote>“更有吸引力”</blockquote></p><p> “Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”</p><p><blockquote>“更多更具吸引力的型号正在问世，”米勒说。“你把这一点与激励因素结合起来，这些就是推动这种更乐观观点的原材料。”</blockquote></p><p> The EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.</p><p><blockquote>安永的研究还认为，现在20多岁和30多岁的千禧一代有助于推动电动汽车的采用。这些消费者在冠状病毒影响下拒绝拼车和公共交通的推动下，正在接受拥有汽车。米勒说，其中30%的人想驾驶电动汽车。</blockquote></p><p> “The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.</p><p><blockquote>米勒说：“我们看到的千禧一代的观点显然更倾向于购买电动汽车。”</blockquote></p><p> Additionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.</p><p><blockquote>此外，政府对电动汽车的购买激励措施以及城市和州对内燃机的拟议禁令相结合，正在加速电池驱动汽车的采用。</blockquote></p><p> Europe is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.</p><p><blockquote>预计到2031年，欧洲的电动汽车销量将处于领先地位，届时中国将成为全球最大的电动汽车市场。</blockquote></p><p> Vehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.</p><p><blockquote>预计到2025年，汽油和柴油动力汽车仍将占所有轻型汽车注册量的三分之二左右，但这将比五年前下降12个百分点。安永预测，到2030年，非电动汽车将占轻型汽车注册总量的一半以下。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-23 07:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.</p><p><blockquote>（彭博社）——根据一项新的研究，随着更严格的法规和不断上升的兴趣推动了对零排放交通的需求，全球电动汽车将在2033年到来，比之前的预期提前了五年。</blockquote></p><p> Consultant Ernst &amp; Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.</p><p><blockquote>咨询公司安永会计师事务所(Ernst&amp;Young LLP)目前预计，在全球最大的汽车市场欧洲、中国和美国，电动汽车销量将在12年内超过化石燃料燃烧器。安永使用人工智能预测工具预测，到2045年，非电动汽车销量预计将骤降至全球汽车市场的1%以下。</blockquote></p><p> Strict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.</p><p><blockquote>政府应对气候变化的严格要求正在推动欧洲和中国的需求，在这些国家，汽车制造商和消费者因销售和购买传统汽油和柴油汽车而面临越来越多的经济处罚。安永预计欧洲将引领电动化潮流，到2028年，零排放车型的销量将超过所有其他推进系统。安永预测，这一临界点将于2033年在中国到来，2036年在美国到来。</blockquote></p><p> The U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.</p><p><blockquote>美国落后于世界其他主要市场，因为唐纳德·特朗普总统执政期间放松了燃油经济性法规。自1月份上任以来，乔·拜登总统重新加入了巴黎气候协议，并提议斥资1740亿美元加速向电动汽车的转变，包括在全国安装50万个充电站。</blockquote></p><p> “The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”</p><p><blockquote>安永全球先进制造和移动出行负责人兰迪·米勒在接受采访时表示：“我们认为拜登政府的监管环境是一个很大的贡献者，因为他有雄心勃勃的目标。”“这种对美洲的影响将产生增压效应。”</blockquote></p><p> There also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.</p><p><blockquote>消费者对电动汽车的需求也在不断增长，从特斯拉公司热销的Model 3到传统汽车制造商的新型电动车型，例如通用汽车公司的电池驱动悍马卡车和福特汽车公司的F-150闪电皮卡。据咨询公司AlixPartners称，目前全球汽车制造商对电池驱动车型的投资超过2300亿美元。</blockquote></p><p> ‘More Appealing’</p><p><blockquote>“更有吸引力”</blockquote></p><p> “Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”</p><p><blockquote>“更多更具吸引力的型号正在问世，”米勒说。“你把这一点与激励因素结合起来，这些就是推动这种更乐观观点的原材料。”</blockquote></p><p> The EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.</p><p><blockquote>安永的研究还认为，现在20多岁和30多岁的千禧一代有助于推动电动汽车的采用。这些消费者在冠状病毒影响下拒绝拼车和公共交通的推动下，正在接受拥有汽车。米勒说，其中30%的人想驾驶电动汽车。</blockquote></p><p> “The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.</p><p><blockquote>米勒说：“我们看到的千禧一代的观点显然更倾向于购买电动汽车。”</blockquote></p><p> Additionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.</p><p><blockquote>此外，政府对电动汽车的购买激励措施以及城市和州对内燃机的拟议禁令相结合，正在加速电池驱动汽车的采用。</blockquote></p><p> Europe is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.</p><p><blockquote>预计到2031年，欧洲的电动汽车销量将处于领先地位，届时中国将成为全球最大的电动汽车市场。</blockquote></p><p> Vehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.</p><p><blockquote>预计到2025年，汽油和柴油动力汽车仍将占所有轻型汽车注册量的三分之二左右，但这将比五年前下降12个百分点。安永预测，到2030年，非电动汽车将占轻型汽车注册总量的一半以下。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","NIO":"蔚来"},"source_url":"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123710128","content_text":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.\nConsultant Ernst & Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.\nStrict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.\nThe U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.\n“The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”\nThere also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.\n‘More Appealing’\n“Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”\nThe EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.\n“The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.\nAdditionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.\nEurope is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.\nVehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.","news_type":1,"symbols_score_info":{"NIO":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2560,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123597682,"gmtCreate":1624428375546,"gmtModify":1634006238087,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"What","listText":"What","text":"What","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123597682","repostId":"1123710128","repostType":4,"repost":{"id":"1123710128","kind":"news","pubTimestamp":1624406277,"share":"https://www.laohu8.com/m/news/1123710128?lang=zh_CN&edition=full","pubTime":"2021-06-23 07:57","market":"us","language":"en","title":"EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1123710128","media":"Bloomberg","summary":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than prev","content":"<p>(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.</p><p><blockquote>（彭博社）——根据一项新的研究，随着更严格的法规和不断上升的兴趣推动了对零排放交通的需求，全球电动汽车将在2033年到来，比之前的预期提前了五年。</blockquote></p><p> Consultant Ernst &amp; Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.</p><p><blockquote>咨询公司安永会计师事务所(Ernst&amp;Young LLP)目前预计，在全球最大的汽车市场欧洲、中国和美国，电动汽车销量将在12年内超过化石燃料燃烧器。安永使用人工智能预测工具预测，到2045年，非电动汽车销量预计将骤降至全球汽车市场的1%以下。</blockquote></p><p> Strict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.</p><p><blockquote>政府应对气候变化的严格要求正在推动欧洲和中国的需求，在这些国家，汽车制造商和消费者因销售和购买传统汽油和柴油汽车而面临越来越多的经济处罚。安永预计欧洲将引领电动化潮流，到2028年，零排放车型的销量将超过所有其他推进系统。安永预测，这一临界点将于2033年在中国到来，2036年在美国到来。</blockquote></p><p> The U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.</p><p><blockquote>美国落后于世界其他主要市场，因为唐纳德·特朗普总统执政期间放松了燃油经济性法规。自1月份上任以来，乔·拜登总统重新加入了巴黎气候协议，并提议斥资1740亿美元加速向电动汽车的转变，包括在全国安装50万个充电站。</blockquote></p><p> “The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”</p><p><blockquote>安永全球先进制造和移动出行负责人兰迪·米勒在接受采访时表示：“我们认为拜登政府的监管环境是一个很大的贡献者，因为他有雄心勃勃的目标。”“这种对美洲的影响将产生增压效应。”</blockquote></p><p> There also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.</p><p><blockquote>消费者对电动汽车的需求也在不断增长，从特斯拉公司热销的Model 3到传统汽车制造商的新型电动车型，例如通用汽车公司的电池驱动悍马卡车和福特汽车公司的F-150闪电皮卡。据咨询公司AlixPartners称，目前全球汽车制造商对电池驱动车型的投资超过2300亿美元。</blockquote></p><p> ‘More Appealing’</p><p><blockquote>“更有吸引力”</blockquote></p><p> “Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”</p><p><blockquote>“更多更具吸引力的型号正在问世，”米勒说。“你把这一点与激励因素结合起来，这些就是推动这种更乐观观点的原材料。”</blockquote></p><p> The EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.</p><p><blockquote>安永的研究还认为，现在20多岁和30多岁的千禧一代有助于推动电动汽车的采用。这些消费者在冠状病毒影响下拒绝拼车和公共交通的推动下，正在接受拥有汽车。米勒说，其中30%的人想驾驶电动汽车。</blockquote></p><p> “The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.</p><p><blockquote>米勒说：“我们看到的千禧一代的观点显然更倾向于购买电动汽车。”</blockquote></p><p> Additionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.</p><p><blockquote>此外，政府对电动汽车的购买激励措施以及城市和州对内燃机的拟议禁令相结合，正在加速电池驱动汽车的采用。</blockquote></p><p> Europe is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.</p><p><blockquote>预计到2031年，欧洲的电动汽车销量将处于领先地位，届时中国将成为全球最大的电动汽车市场。</blockquote></p><p> Vehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.</p><p><blockquote>预计到2025年，汽油和柴油动力汽车仍将占所有轻型汽车注册量的三分之二左右，但这将比五年前下降12个百分点。安永预测，到2030年，非电动汽车将占轻型汽车注册总量的一半以下。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-23 07:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.</p><p><blockquote>（彭博社）——根据一项新的研究，随着更严格的法规和不断上升的兴趣推动了对零排放交通的需求，全球电动汽车将在2033年到来，比之前的预期提前了五年。</blockquote></p><p> Consultant Ernst &amp; Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.</p><p><blockquote>咨询公司安永会计师事务所(Ernst&amp;Young LLP)目前预计，在全球最大的汽车市场欧洲、中国和美国，电动汽车销量将在12年内超过化石燃料燃烧器。安永使用人工智能预测工具预测，到2045年，非电动汽车销量预计将骤降至全球汽车市场的1%以下。</blockquote></p><p> Strict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.</p><p><blockquote>政府应对气候变化的严格要求正在推动欧洲和中国的需求，在这些国家，汽车制造商和消费者因销售和购买传统汽油和柴油汽车而面临越来越多的经济处罚。安永预计欧洲将引领电动化潮流，到2028年，零排放车型的销量将超过所有其他推进系统。安永预测，这一临界点将于2033年在中国到来，2036年在美国到来。</blockquote></p><p> The U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.</p><p><blockquote>美国落后于世界其他主要市场，因为唐纳德·特朗普总统执政期间放松了燃油经济性法规。自1月份上任以来，乔·拜登总统重新加入了巴黎气候协议，并提议斥资1740亿美元加速向电动汽车的转变，包括在全国安装50万个充电站。</blockquote></p><p> “The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”</p><p><blockquote>安永全球先进制造和移动出行负责人兰迪·米勒在接受采访时表示：“我们认为拜登政府的监管环境是一个很大的贡献者，因为他有雄心勃勃的目标。”“这种对美洲的影响将产生增压效应。”</blockquote></p><p> There also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.</p><p><blockquote>消费者对电动汽车的需求也在不断增长，从特斯拉公司热销的Model 3到传统汽车制造商的新型电动车型，例如通用汽车公司的电池驱动悍马卡车和福特汽车公司的F-150闪电皮卡。据咨询公司AlixPartners称，目前全球汽车制造商对电池驱动车型的投资超过2300亿美元。</blockquote></p><p> ‘More Appealing’</p><p><blockquote>“更有吸引力”</blockquote></p><p> “Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”</p><p><blockquote>“更多更具吸引力的型号正在问世，”米勒说。“你把这一点与激励因素结合起来，这些就是推动这种更乐观观点的原材料。”</blockquote></p><p> The EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.</p><p><blockquote>安永的研究还认为，现在20多岁和30多岁的千禧一代有助于推动电动汽车的采用。这些消费者在冠状病毒影响下拒绝拼车和公共交通的推动下，正在接受拥有汽车。米勒说，其中30%的人想驾驶电动汽车。</blockquote></p><p> “The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.</p><p><blockquote>米勒说：“我们看到的千禧一代的观点显然更倾向于购买电动汽车。”</blockquote></p><p> Additionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.</p><p><blockquote>此外，政府对电动汽车的购买激励措施以及城市和州对内燃机的拟议禁令相结合，正在加速电池驱动汽车的采用。</blockquote></p><p> Europe is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.</p><p><blockquote>预计到2031年，欧洲的电动汽车销量将处于领先地位，届时中国将成为全球最大的电动汽车市场。</blockquote></p><p> Vehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.</p><p><blockquote>预计到2025年，汽油和柴油动力汽车仍将占所有轻型汽车注册量的三分之二左右，但这将比五年前下降12个百分点。安永预测，到2030年，非电动汽车将占轻型汽车注册总量的一半以下。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","NIO":"蔚来"},"source_url":"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123710128","content_text":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.\nConsultant Ernst & Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.\nStrict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.\nThe U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.\n“The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”\nThere also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.\n‘More Appealing’\n“Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”\nThe EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.\n“The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.\nAdditionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.\nEurope is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.\nVehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.","news_type":1,"symbols_score_info":{"NIO":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1248,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123597355,"gmtCreate":1624428362077,"gmtModify":1634006238208,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Yums","listText":"Yums","text":"Yums","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123597355","repostId":"1126010678","repostType":4,"repost":{"id":"1126010678","kind":"news","pubTimestamp":1624412603,"share":"https://www.laohu8.com/m/news/1126010678?lang=zh_CN&edition=full","pubTime":"2021-06-23 09:43","market":"us","language":"en","title":"Krispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转向线上，Krispy Kreme寻求6.4亿美元IPO</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1126010678","media":"Bloomberg","summary":"(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise a","content":"<p>(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering.</p><p><blockquote>（彭博）——JAB Holdings BV旗下的甜甜圈连锁店Krispy Kreme Inc.正寻求通过首次公开募股筹集高达6.4亿美元的资金。</blockquote></p><p> The company said in a filing Tuesday that it plans to sell almost 27 million shares for $21 to $24 apiece. At the top end of the range, Krispy Kreme would have a market value of $3.86 billion based on the outstanding shares listed in the filing with the U.S. Securities and Exchange Commission.</p><p><blockquote>该公司在周二提交的文件中表示，计划以每股21至24美元的价格出售近2700万股股票。根据向美国证券交易委员会提交的文件中列出的已发行股票，Krispy Kreme的市值将达到38.6亿美元。</blockquote></p><p> Amid photos of doughnuts dripping with sugary glaze and dotted with sprinkles, the company declares in the filing that its purpose is “to touch and enhance lives through the joy of Krispy Kreme.”</p><p><blockquote>在甜甜圈滴着糖釉并点缀着糖屑的照片中，该公司在文件中宣称，其目的是“通过Krispy Kreme的快乐来感动和改善生活”。</blockquote></p><p> Since its acquisition by Luxembourg-based conglomerate JAB in 2016, Krispy Kreme has expanded its online presence. Its e-commerce business now accounts for close to a fifth of sales in the U.S., fueled by its Insomnia Cookies delivery concept.</p><p><blockquote>自2016年被卢森堡企业集团JAB收购以来，Krispy Kreme扩大了其在线业务。在失眠饼干配送概念的推动下，其电子商务业务目前占美国销售额的近五分之一。</blockquote></p><p> Net revenue for the Charlotte, North Carolina-based chain rose 23% to $322 million in the quarter ended April 4, according to the filing. Its net loss for the quarter shrunk from $11 million in 2020 to $378,000 this year.</p><p><blockquote>文件显示，截至4月4日的季度，这家总部位于北卡罗来纳州夏洛特的连锁店的净收入增长了23%，达到3.22亿美元。该季度净亏损从2020年的1100万美元缩小至今年的37.8万美元。</blockquote></p><p> Krispy Kreme plans to use proceeds from the IPO to pay down debt and buy back shares from certain executives, as well as for general corporate purposes, according to the filing. JAB will continue to own almost 78% of the company’s shares after the IPO.</p><p><blockquote>文件显示，Krispy Kreme计划将IPO所得用于偿还债务、从某些高管手中回购股票以及用于一般公司用途。IPO后，JAB将继续持有该公司近78%的股份。</blockquote></p><p> The offering is being led by JPMorgan Chase &amp; Co., Morgan Stanley, Bank of America Corp. and Citigroup Inc. The company plans to list on the Nasdaq Global Select Market under the symbol DNUT.</p><p><blockquote>此次发行由摩根大通、摩根士丹利、美国银行和花旗集团牵头。该公司计划在纳斯达克全球精选市场上市，代码为DNUT。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Krispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转向线上，Krispy Kreme寻求6.4亿美元IPO</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKrispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转向线上，Krispy Kreme寻求6.4亿美元IPO</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-23 09:43</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering.</p><p><blockquote>（彭博）——JAB Holdings BV旗下的甜甜圈连锁店Krispy Kreme Inc.正寻求通过首次公开募股筹集高达6.4亿美元的资金。</blockquote></p><p> The company said in a filing Tuesday that it plans to sell almost 27 million shares for $21 to $24 apiece. At the top end of the range, Krispy Kreme would have a market value of $3.86 billion based on the outstanding shares listed in the filing with the U.S. Securities and Exchange Commission.</p><p><blockquote>该公司在周二提交的文件中表示，计划以每股21至24美元的价格出售近2700万股股票。根据向美国证券交易委员会提交的文件中列出的已发行股票，Krispy Kreme的市值将达到38.6亿美元。</blockquote></p><p> Amid photos of doughnuts dripping with sugary glaze and dotted with sprinkles, the company declares in the filing that its purpose is “to touch and enhance lives through the joy of Krispy Kreme.”</p><p><blockquote>在甜甜圈滴着糖釉并点缀着糖屑的照片中，该公司在文件中宣称，其目的是“通过Krispy Kreme的快乐来感动和改善生活”。</blockquote></p><p> Since its acquisition by Luxembourg-based conglomerate JAB in 2016, Krispy Kreme has expanded its online presence. Its e-commerce business now accounts for close to a fifth of sales in the U.S., fueled by its Insomnia Cookies delivery concept.</p><p><blockquote>自2016年被卢森堡企业集团JAB收购以来，Krispy Kreme扩大了其在线业务。在失眠饼干配送概念的推动下，其电子商务业务目前占美国销售额的近五分之一。</blockquote></p><p> Net revenue for the Charlotte, North Carolina-based chain rose 23% to $322 million in the quarter ended April 4, according to the filing. Its net loss for the quarter shrunk from $11 million in 2020 to $378,000 this year.</p><p><blockquote>文件显示，截至4月4日的季度，这家总部位于北卡罗来纳州夏洛特的连锁店的净收入增长了23%，达到3.22亿美元。该季度净亏损从2020年的1100万美元缩小至今年的37.8万美元。</blockquote></p><p> Krispy Kreme plans to use proceeds from the IPO to pay down debt and buy back shares from certain executives, as well as for general corporate purposes, according to the filing. JAB will continue to own almost 78% of the company’s shares after the IPO.</p><p><blockquote>文件显示，Krispy Kreme计划将IPO所得用于偿还债务、从某些高管手中回购股票以及用于一般公司用途。IPO后，JAB将继续持有该公司近78%的股份。</blockquote></p><p> The offering is being led by JPMorgan Chase &amp; Co., Morgan Stanley, Bank of America Corp. and Citigroup Inc. The company plans to list on the Nasdaq Global Select Market under the symbol DNUT.</p><p><blockquote>此次发行由摩根大通、摩根士丹利、美国银行和花旗集团牵头。该公司计划在纳斯达克全球精选市场上市，代码为DNUT。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DNUT":"Krispy Kreme, Inc."},"source_url":"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126010678","content_text":"(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering.\nThe company said in a filing Tuesday that it plans to sell almost 27 million shares for $21 to $24 apiece. At the top end of the range, Krispy Kreme would have a market value of $3.86 billion based on the outstanding shares listed in the filing with the U.S. Securities and Exchange Commission.\nAmid photos of doughnuts dripping with sugary glaze and dotted with sprinkles, the company declares in the filing that its purpose is “to touch and enhance lives through the joy of Krispy Kreme.”\nSince its acquisition by Luxembourg-based conglomerate JAB in 2016, Krispy Kreme has expanded its online presence. Its e-commerce business now accounts for close to a fifth of sales in the U.S., fueled by its Insomnia Cookies delivery concept.\nNet revenue for the Charlotte, North Carolina-based chain rose 23% to $322 million in the quarter ended April 4, according to the filing. Its net loss for the quarter shrunk from $11 million in 2020 to $378,000 this year.\nKrispy Kreme plans to use proceeds from the IPO to pay down debt and buy back shares from certain executives, as well as for general corporate purposes, according to the filing. JAB will continue to own almost 78% of the company’s shares after the IPO.\nThe offering is being led by JPMorgan Chase & Co., Morgan Stanley, Bank of America Corp. and Citigroup Inc. The company plans to list on the Nasdaq Global Select Market under the symbol DNUT.","news_type":1,"symbols_score_info":{"DNUT":0.9}},"isVote":1,"tweetType":1,"viewCount":3183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123594843,"gmtCreate":1624428337982,"gmtModify":1634006238572,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123594843","repostId":"2145057786","repostType":4,"isVote":1,"tweetType":1,"viewCount":2992,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123595713,"gmtCreate":1624428311132,"gmtModify":1634006238814,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123595713","repostId":"2145066250","repostType":4,"isVote":1,"tweetType":1,"viewCount":2502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123592750,"gmtCreate":1624428287070,"gmtModify":1634006239664,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123592750","repostId":"1192380860","repostType":4,"isVote":1,"tweetType":1,"viewCount":1561,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123592828,"gmtCreate":1624428233064,"gmtModify":1634006240151,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123592828","repostId":"1174011543","repostType":4,"repost":{"id":"1174011543","kind":"news","pubTimestamp":1624425845,"share":"https://www.laohu8.com/m/news/1174011543?lang=zh_CN&edition=full","pubTime":"2021-06-23 13:24","market":"us","language":"en","title":"FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管一些员工表示担忧，FDA还是批准了百健(Biogen)的阿尔茨海默病药物</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174011543","media":"WSJ","summary":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the obje","content":"<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.</p><p><blockquote>美国。根据最新发布的内部备忘录，美国食品和药物管理局不顾该机构统计学家的反对，批准了十年来第一种新的阿尔茨海默氏症药物，他们表示没有足够的证据支持批准。</blockquote></p><p> In the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.</p><p><blockquote>在周二发布的内部备忘录中，FDA官员讨论了是否批准BiogenInc.BIIB-1.71%的药物，尽管该机构药物统计办公室提出了反对意见，该办公室表示，临床试验数据达不到将新产品投放市场通常所需的证据。</blockquote></p><p> Ultimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.</p><p><blockquote>备忘录显示，最终，高级官员认为，表明该药物有效的证据虽然尚无定论，但足以让医生和患者自行决定是否服用。</blockquote></p><p> “FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”</p><p><blockquote>FDA新药办公室主任Peter Stein在一份备忘录中写道：“那么，FDA面临的情况是，临床终点的现有证据不足以达到我们标准批准aducanumab所需的证据。”他对批准的支持。“与此同时，[阿尔茨海默氏症]患者患有严重、进行性、最终致命的疾病，并且迫切需要治疗。”</blockquote></p><p> The FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.</p><p><blockquote>FDA公开了其内部审议情况，因为它面临一些医生和科学家对6月7日批准这种名为Aduhelm的药物的批评。</blockquote></p><p> The critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.</p><p><blockquote>批评者表示，FDA忽视了通常要求制药商遵守的科学标准，可能会促使联邦政府在一种可能不起作用的药物上花费数十亿美元。</blockquote></p><p> “While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”</p><p><blockquote>“虽然我完全支持该中心最近批准该疗法的决定，但我承认对这一决定存在不同意见，包括FDA内部，并且围绕我们的审查流程和我们考虑支持该疗法的数据可能会继续存在问题FDA代理专员珍妮特·伍德库克(Janet Woodcock)表示。“最终，FDA一组经验丰富的医学审查人员得出结论，有足够的证据通过加速批准途径批准阿尔茨海默病疗法。”</blockquote></p><p> Supporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.</p><p><blockquote>支持者表示，FDA的决定为缺乏任何有望减缓阿尔茨海默氏症进展的药物的患者提供了生命线，并且该决定可能会刺激更多、更好药物的开发。</blockquote></p><p> The agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.</p><p><blockquote>该机构通常会在做出决定后发布批准文件，尽管通常不会像这次那么快。83页的备忘录似乎是FDA审议的一部分，很大程度上反映了高级官员的交流。</blockquote></p><p> Tristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.</p><p><blockquote>一份内部文件显示，FDA生物统计学审查员Tristan Massie“不同意所有数据提供了足够的证据来支持aducanumab在阿尔茨海默病中的疗效，也不建议批准”。</blockquote></p><p> Patrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”</p><p><blockquote>FDA最高级别的药物评估官员帕特里齐亚·卡瓦佐尼(Patrizia Cavazzoni)在另一份备忘录中写道，该机构的药物生物统计办公室“为其建议提供了文件，即申请中没有提供实质性的有效性证据”。</blockquote></p><p> That office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.</p><p><blockquote>该办公室的完整反对分析并未包含在周二提供的材料中，但其中部分内容包含在内。</blockquote></p><p> Despite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.</p><p><blockquote>尽管遭到反对，卡瓦佐尼博士写道，百健已经满足了“加速批准”的要求，这是一种监管许可，即使药物满足了未满足的需求，其临床益处仍存在不确定性，也可以上市。严重疾病并对疾病的生物标志有影响。</blockquote></p><p> Dr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”</p><p><blockquote>Cavazzoni博士写道，Aduhelm符合这一标准，因为它可以减少一种称为淀粉样蛋白的粘性物质，这种物质“很可能预测临床益处”。</blockquote></p><p> Some doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.</p><p><blockquote>一些医生和科学家表示，针对淀粉样蛋白斑块尚未被证明可以减缓阿尔茨海默氏症。建议FDA拒绝该药物的顾问小组的一些成员以该机构的批准为由退出了该委员会。</blockquote></p><p> Biogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.</p><p><blockquote>Biogen列出的Aduhelm价格为每年56,000美元，患者和医疗保险也可能面临检测费用。</blockquote></p><p> About six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.</p><p><blockquote>大约600万美国人患有阿尔茨海默氏症，这是一种渐进性疾病，会剥夺人们的记忆和认知能力。Biogen表示，其中多达200万人可能会从该药物中受益。</blockquote></p><p> The FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.</p><p><blockquote>FDA的批准导致百健(Biogen)的股价飙升。该公司表示，预计今年该药物的收入很少，部分原因是管理该药物的后勤挑战，但明年销售额将开始增加。</blockquote></p><p> Analysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.</p><p><blockquote>FactSet的数据显示，分析师预计2022年销售额为9.463亿美元。预计2026年销售额将增长至52亿美元。</blockquote></p><p> The memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.</p><p><blockquote>备忘录显示，FDA官员试图平衡Aduhelm低于标准的研究数据与阿尔茨海默病患者及其家人尝试任何可能有帮助的新治疗方法的愿望。</blockquote></p><p></p><p> “There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.</p><p><blockquote>斯坦博士写道：“临床益处仍然存在不确定性。”但他写道，如果FDA等待该公司完成另一项临床研究，“任何批准都将在延迟多年后获得”，患者“可能会遭受不可逆转的脑神经元、认知功能和记忆丧失”。</blockquote></p><p> The FDA said it plans to release more documents regarding its decision making as early as next week.</p><p><blockquote>FDA表示，计划最早在下周发布更多有关其决策的文件。</blockquote></p><p> The FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.</p><p><blockquote>FDA的批准主要基于Biogen启动的两项大型3期临床试验，以证明其药物有助于减缓早期阿尔茨海默氏症患者的认知能力下降。</blockquote></p><p> In March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.</p><p><blockquote>2019年3月，在独立监测委员会得出该药物不太可能帮助患者后，该公司提前停止了研究。</blockquote></p><p> Seven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.</p><p><blockquote>然而，七个月后，该公司做出了令人惊讶的逆转，并表示在对研究停止后获得的试验数据进行额外分析后，现在计划寻求FDA的批准。该公司表示，其分析发现该药物在一项研究中成功，但在第二项研究中失败。</blockquote></p><p> The FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.</p><p><blockquote>FDA备忘录提供了一些关于Biogen大转变的新细节。根据一份“摘要备忘录”文件，2019年6月，该公司会见了FDA官员，双方一致认为这些研究不应停止。</blockquote></p><p> At the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.</p><p><blockquote>在会议上，FDA官员建议Biogen进一步分析这些研究，以了解尽管试验停止且结果相互矛盾，但是否仍有可能从数据中得出结论。</blockquote></p><p> Several months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.</p><p><blockquote>备忘录称，几个月后，即2019年10月，该机构和公司再次会面，并同意这些研究仍可用于评估该药物的有效性。</blockquote></p><p> The following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.</p><p><blockquote>第二天，即10月22日，百健(Biogen)宣布将寻求该药物的批准，这推高了其股价，使其市值增加了数十亿美元。</blockquote></p><p> The company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.</p><p><blockquote>百健(Biogen)首席执行官米歇尔·沃纳索斯(Michel Vounatsos)当时在接受采访时表示，该公司几个月来一直在悄悄重新审查这些数据，但直到最近一次与FDA官员会面时才有信心向前推进。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管一些员工表示担忧，FDA还是批准了百健(Biogen)的阿尔茨海默病药物</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管一些员工表示担忧，FDA还是批准了百健(Biogen)的阿尔茨海默病药物</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">WSJ</strong><span class=\"h-time small\">2021-06-23 13:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.</p><p><blockquote>美国。根据最新发布的内部备忘录，美国食品和药物管理局不顾该机构统计学家的反对，批准了十年来第一种新的阿尔茨海默氏症药物，他们表示没有足够的证据支持批准。</blockquote></p><p> In the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.</p><p><blockquote>在周二发布的内部备忘录中，FDA官员讨论了是否批准BiogenInc.BIIB-1.71%的药物，尽管该机构药物统计办公室提出了反对意见，该办公室表示，临床试验数据达不到将新产品投放市场通常所需的证据。</blockquote></p><p> Ultimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.</p><p><blockquote>备忘录显示，最终，高级官员认为，表明该药物有效的证据虽然尚无定论，但足以让医生和患者自行决定是否服用。</blockquote></p><p> “FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”</p><p><blockquote>FDA新药办公室主任Peter Stein在一份备忘录中写道：“那么，FDA面临的情况是，临床终点的现有证据不足以达到我们标准批准aducanumab所需的证据。”他对批准的支持。“与此同时，[阿尔茨海默氏症]患者患有严重、进行性、最终致命的疾病，并且迫切需要治疗。”</blockquote></p><p> The FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.</p><p><blockquote>FDA公开了其内部审议情况，因为它面临一些医生和科学家对6月7日批准这种名为Aduhelm的药物的批评。</blockquote></p><p> The critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.</p><p><blockquote>批评者表示，FDA忽视了通常要求制药商遵守的科学标准，可能会促使联邦政府在一种可能不起作用的药物上花费数十亿美元。</blockquote></p><p> “While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”</p><p><blockquote>“虽然我完全支持该中心最近批准该疗法的决定，但我承认对这一决定存在不同意见，包括FDA内部，并且围绕我们的审查流程和我们考虑支持该疗法的数据可能会继续存在问题FDA代理专员珍妮特·伍德库克(Janet Woodcock)表示。“最终，FDA一组经验丰富的医学审查人员得出结论，有足够的证据通过加速批准途径批准阿尔茨海默病疗法。”</blockquote></p><p> Supporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.</p><p><blockquote>支持者表示，FDA的决定为缺乏任何有望减缓阿尔茨海默氏症进展的药物的患者提供了生命线，并且该决定可能会刺激更多、更好药物的开发。</blockquote></p><p> The agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.</p><p><blockquote>该机构通常会在做出决定后发布批准文件，尽管通常不会像这次那么快。83页的备忘录似乎是FDA审议的一部分，很大程度上反映了高级官员的交流。</blockquote></p><p> Tristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.</p><p><blockquote>一份内部文件显示，FDA生物统计学审查员Tristan Massie“不同意所有数据提供了足够的证据来支持aducanumab在阿尔茨海默病中的疗效，也不建议批准”。</blockquote></p><p> Patrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”</p><p><blockquote>FDA最高级别的药物评估官员帕特里齐亚·卡瓦佐尼(Patrizia Cavazzoni)在另一份备忘录中写道，该机构的药物生物统计办公室“为其建议提供了文件，即申请中没有提供实质性的有效性证据”。</blockquote></p><p> That office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.</p><p><blockquote>该办公室的完整反对分析并未包含在周二提供的材料中，但其中部分内容包含在内。</blockquote></p><p> Despite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.</p><p><blockquote>尽管遭到反对，卡瓦佐尼博士写道，百健已经满足了“加速批准”的要求，这是一种监管许可，即使药物满足了未满足的需求，其临床益处仍存在不确定性，也可以上市。严重疾病并对疾病的生物标志有影响。</blockquote></p><p> Dr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”</p><p><blockquote>Cavazzoni博士写道，Aduhelm符合这一标准，因为它可以减少一种称为淀粉样蛋白的粘性物质，这种物质“很可能预测临床益处”。</blockquote></p><p> Some doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.</p><p><blockquote>一些医生和科学家表示，针对淀粉样蛋白斑块尚未被证明可以减缓阿尔茨海默氏症。建议FDA拒绝该药物的顾问小组的一些成员以该机构的批准为由退出了该委员会。</blockquote></p><p> Biogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.</p><p><blockquote>Biogen列出的Aduhelm价格为每年56,000美元，患者和医疗保险也可能面临检测费用。</blockquote></p><p> About six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.</p><p><blockquote>大约600万美国人患有阿尔茨海默氏症，这是一种渐进性疾病，会剥夺人们的记忆和认知能力。Biogen表示，其中多达200万人可能会从该药物中受益。</blockquote></p><p> The FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.</p><p><blockquote>FDA的批准导致百健(Biogen)的股价飙升。该公司表示，预计今年该药物的收入很少，部分原因是管理该药物的后勤挑战，但明年销售额将开始增加。</blockquote></p><p> Analysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.</p><p><blockquote>FactSet的数据显示，分析师预计2022年销售额为9.463亿美元。预计2026年销售额将增长至52亿美元。</blockquote></p><p> The memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.</p><p><blockquote>备忘录显示，FDA官员试图平衡Aduhelm低于标准的研究数据与阿尔茨海默病患者及其家人尝试任何可能有帮助的新治疗方法的愿望。</blockquote></p><p></p><p> “There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.</p><p><blockquote>斯坦博士写道：“临床益处仍然存在不确定性。”但他写道，如果FDA等待该公司完成另一项临床研究，“任何批准都将在延迟多年后获得”，患者“可能会遭受不可逆转的脑神经元、认知功能和记忆丧失”。</blockquote></p><p> The FDA said it plans to release more documents regarding its decision making as early as next week.</p><p><blockquote>FDA表示，计划最早在下周发布更多有关其决策的文件。</blockquote></p><p> The FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.</p><p><blockquote>FDA的批准主要基于Biogen启动的两项大型3期临床试验，以证明其药物有助于减缓早期阿尔茨海默氏症患者的认知能力下降。</blockquote></p><p> In March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.</p><p><blockquote>2019年3月，在独立监测委员会得出该药物不太可能帮助患者后，该公司提前停止了研究。</blockquote></p><p> Seven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.</p><p><blockquote>然而，七个月后，该公司做出了令人惊讶的逆转，并表示在对研究停止后获得的试验数据进行额外分析后，现在计划寻求FDA的批准。该公司表示，其分析发现该药物在一项研究中成功，但在第二项研究中失败。</blockquote></p><p> The FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.</p><p><blockquote>FDA备忘录提供了一些关于Biogen大转变的新细节。根据一份“摘要备忘录”文件，2019年6月，该公司会见了FDA官员，双方一致认为这些研究不应停止。</blockquote></p><p> At the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.</p><p><blockquote>在会议上，FDA官员建议Biogen进一步分析这些研究，以了解尽管试验停止且结果相互矛盾，但是否仍有可能从数据中得出结论。</blockquote></p><p> Several months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.</p><p><blockquote>备忘录称，几个月后，即2019年10月，该机构和公司再次会面，并同意这些研究仍可用于评估该药物的有效性。</blockquote></p><p> The following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.</p><p><blockquote>第二天，即10月22日，百健(Biogen)宣布将寻求该药物的批准，这推高了其股价，使其市值增加了数十亿美元。</blockquote></p><p> The company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.</p><p><blockquote>百健(Biogen)首席执行官米歇尔·沃纳索斯(Michel Vounatsos)当时在接受采访时表示，该公司几个月来一直在悄悄重新审查这些数据，但直到最近一次与FDA官员会面时才有信心向前推进。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2\">WSJ</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174011543","content_text":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.\nIn the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.\nUltimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.\n“FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”\nThe FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.\nThe critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.\n“While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”\nSupporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.\nThe agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.\nTristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.\nPatrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”\nThat office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.\nDespite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.\nDr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”\nSome doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.\nBiogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.\nAbout six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.\nThe FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.\nAnalysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.\nThe memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.\n“There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.\nThe FDA said it plans to release more documents regarding its decision making as early as next week.\nThe FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.\nIn March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.\nSeven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.\nThe FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.\nAt the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.\nSeveral months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.\nThe following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.\nThe company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":2865,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":123566429,"gmtCreate":1624429967061,"gmtModify":1634006224487,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123566429","repostId":"114899451","repostType":1,"repost":{"id":114899451,"gmtCreate":1623063308869,"gmtModify":1631884627596,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"36984908995200","idStr":"36984908995200"},"themes":[],"title":"【老虎7周年】集卡瓜分百万奖金","htmlText":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可参与活动</a> &#x1;如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。&#x1;如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 &#x1; &#x1;如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。&#x1; 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP &gt; 我的 &gt; 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","listText":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可参与活动</a> &#x1;如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。&#x1;如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 &#x1; &#x1;如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。&#x1; 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP &gt; 我的 &gt; 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","text":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ 戳我即可参与活动 \u0001如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。\u0001如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 \u0001 \u0001如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。\u0001 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP > 我的 > 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","images":[{"img":"https://static.tigerbbs.com/ab28db31a19b458d604a8bf02becddd3","width":"415","height":"125"},{"img":"https://static.tigerbbs.com/5227ebb594fe55b532c840acef147d7b","width":"415","height":"495"},{"img":"https://static.tigerbbs.com/92e88357b534f504b3088bc22f577a83","width":"415","height":"326"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114899451","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":8,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123518556,"gmtCreate":1624429005975,"gmtModify":1634006232788,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123518556","repostId":"2145671770","repostType":2,"isVote":1,"tweetType":1,"viewCount":3241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123510136,"gmtCreate":1624428873625,"gmtModify":1634006234187,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123510136","repostId":"1123710128","repostType":4,"repost":{"id":"1123710128","kind":"news","pubTimestamp":1624406277,"share":"https://www.laohu8.com/m/news/1123710128?lang=zh_CN&edition=full","pubTime":"2021-06-23 07:57","market":"us","language":"en","title":"EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1123710128","media":"Bloomberg","summary":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than prev","content":"<p>(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.</p><p><blockquote>（彭博社）——根据一项新的研究，随着更严格的法规和不断上升的兴趣推动了对零排放交通的需求，全球电动汽车将在2033年到来，比之前的预期提前了五年。</blockquote></p><p> Consultant Ernst &amp; Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.</p><p><blockquote>咨询公司安永会计师事务所(Ernst&amp;Young LLP)目前预计，在全球最大的汽车市场欧洲、中国和美国，电动汽车销量将在12年内超过化石燃料燃烧器。安永使用人工智能预测工具预测，到2045年，非电动汽车销量预计将骤降至全球汽车市场的1%以下。</blockquote></p><p> Strict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.</p><p><blockquote>政府应对气候变化的严格要求正在推动欧洲和中国的需求，在这些国家，汽车制造商和消费者因销售和购买传统汽油和柴油汽车而面临越来越多的经济处罚。安永预计欧洲将引领电动化潮流，到2028年，零排放车型的销量将超过所有其他推进系统。安永预测，这一临界点将于2033年在中国到来，2036年在美国到来。</blockquote></p><p> The U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.</p><p><blockquote>美国落后于世界其他主要市场，因为唐纳德·特朗普总统执政期间放松了燃油经济性法规。自1月份上任以来，乔·拜登总统重新加入了巴黎气候协议，并提议斥资1740亿美元加速向电动汽车的转变，包括在全国安装50万个充电站。</blockquote></p><p> “The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”</p><p><blockquote>安永全球先进制造和移动出行负责人兰迪·米勒在接受采访时表示：“我们认为拜登政府的监管环境是一个很大的贡献者，因为他有雄心勃勃的目标。”“这种对美洲的影响将产生增压效应。”</blockquote></p><p> There also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.</p><p><blockquote>消费者对电动汽车的需求也在不断增长，从特斯拉公司热销的Model 3到传统汽车制造商的新型电动车型，例如通用汽车公司的电池驱动悍马卡车和福特汽车公司的F-150闪电皮卡。据咨询公司AlixPartners称，目前全球汽车制造商对电池驱动车型的投资超过2300亿美元。</blockquote></p><p> ‘More Appealing’</p><p><blockquote>“更有吸引力”</blockquote></p><p> “Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”</p><p><blockquote>“更多更具吸引力的型号正在问世，”米勒说。“你把这一点与激励因素结合起来，这些就是推动这种更乐观观点的原材料。”</blockquote></p><p> The EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.</p><p><blockquote>安永的研究还认为，现在20多岁和30多岁的千禧一代有助于推动电动汽车的采用。这些消费者在冠状病毒影响下拒绝拼车和公共交通的推动下，正在接受拥有汽车。米勒说，其中30%的人想驾驶电动汽车。</blockquote></p><p> “The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.</p><p><blockquote>米勒说：“我们看到的千禧一代的观点显然更倾向于购买电动汽车。”</blockquote></p><p> Additionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.</p><p><blockquote>此外，政府对电动汽车的购买激励措施以及城市和州对内燃机的拟议禁令相结合，正在加速电池驱动汽车的采用。</blockquote></p><p> Europe is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.</p><p><blockquote>预计到2031年，欧洲的电动汽车销量将处于领先地位，届时中国将成为全球最大的电动汽车市场。</blockquote></p><p> Vehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.</p><p><blockquote>预计到2025年，汽油和柴油动力汽车仍将占所有轻型汽车注册量的三分之二左右，但这将比五年前下降12个百分点。安永预测，到2030年，非电动汽车将占轻型汽车注册总量的一半以下。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-23 07:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.</p><p><blockquote>（彭博社）——根据一项新的研究，随着更严格的法规和不断上升的兴趣推动了对零排放交通的需求，全球电动汽车将在2033年到来，比之前的预期提前了五年。</blockquote></p><p> Consultant Ernst &amp; Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.</p><p><blockquote>咨询公司安永会计师事务所(Ernst&amp;Young LLP)目前预计，在全球最大的汽车市场欧洲、中国和美国，电动汽车销量将在12年内超过化石燃料燃烧器。安永使用人工智能预测工具预测，到2045年，非电动汽车销量预计将骤降至全球汽车市场的1%以下。</blockquote></p><p> Strict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.</p><p><blockquote>政府应对气候变化的严格要求正在推动欧洲和中国的需求，在这些国家，汽车制造商和消费者因销售和购买传统汽油和柴油汽车而面临越来越多的经济处罚。安永预计欧洲将引领电动化潮流，到2028年，零排放车型的销量将超过所有其他推进系统。安永预测，这一临界点将于2033年在中国到来，2036年在美国到来。</blockquote></p><p> The U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.</p><p><blockquote>美国落后于世界其他主要市场，因为唐纳德·特朗普总统执政期间放松了燃油经济性法规。自1月份上任以来，乔·拜登总统重新加入了巴黎气候协议，并提议斥资1740亿美元加速向电动汽车的转变，包括在全国安装50万个充电站。</blockquote></p><p> “The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”</p><p><blockquote>安永全球先进制造和移动出行负责人兰迪·米勒在接受采访时表示：“我们认为拜登政府的监管环境是一个很大的贡献者，因为他有雄心勃勃的目标。”“这种对美洲的影响将产生增压效应。”</blockquote></p><p> There also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.</p><p><blockquote>消费者对电动汽车的需求也在不断增长，从特斯拉公司热销的Model 3到传统汽车制造商的新型电动车型，例如通用汽车公司的电池驱动悍马卡车和福特汽车公司的F-150闪电皮卡。据咨询公司AlixPartners称，目前全球汽车制造商对电池驱动车型的投资超过2300亿美元。</blockquote></p><p> ‘More Appealing’</p><p><blockquote>“更有吸引力”</blockquote></p><p> “Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”</p><p><blockquote>“更多更具吸引力的型号正在问世，”米勒说。“你把这一点与激励因素结合起来，这些就是推动这种更乐观观点的原材料。”</blockquote></p><p> The EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.</p><p><blockquote>安永的研究还认为，现在20多岁和30多岁的千禧一代有助于推动电动汽车的采用。这些消费者在冠状病毒影响下拒绝拼车和公共交通的推动下，正在接受拥有汽车。米勒说，其中30%的人想驾驶电动汽车。</blockquote></p><p> “The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.</p><p><blockquote>米勒说：“我们看到的千禧一代的观点显然更倾向于购买电动汽车。”</blockquote></p><p> Additionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.</p><p><blockquote>此外，政府对电动汽车的购买激励措施以及城市和州对内燃机的拟议禁令相结合，正在加速电池驱动汽车的采用。</blockquote></p><p> Europe is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.</p><p><blockquote>预计到2031年，欧洲的电动汽车销量将处于领先地位，届时中国将成为全球最大的电动汽车市场。</blockquote></p><p> Vehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.</p><p><blockquote>预计到2025年，汽油和柴油动力汽车仍将占所有轻型汽车注册量的三分之二左右，但这将比五年前下降12个百分点。安永预测，到2030年，非电动汽车将占轻型汽车注册总量的一半以下。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","NIO":"蔚来"},"source_url":"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123710128","content_text":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.\nConsultant Ernst & Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.\nStrict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.\nThe U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.\n“The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”\nThere also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.\n‘More Appealing’\n“Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”\nThe EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.\n“The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.\nAdditionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.\nEurope is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.\nVehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.","news_type":1,"symbols_score_info":{"NIO":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":2560,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123597682,"gmtCreate":1624428375546,"gmtModify":1634006238087,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"What","listText":"What","text":"What","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123597682","repostId":"1123710128","repostType":4,"repost":{"id":"1123710128","kind":"news","pubTimestamp":1624406277,"share":"https://www.laohu8.com/m/news/1123710128?lang=zh_CN&edition=full","pubTime":"2021-06-23 07:57","market":"us","language":"en","title":"EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1123710128","media":"Bloomberg","summary":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than prev","content":"<p>(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.</p><p><blockquote>（彭博社）——根据一项新的研究，随着更严格的法规和不断上升的兴趣推动了对零排放交通的需求，全球电动汽车将在2033年到来，比之前的预期提前了五年。</blockquote></p><p> Consultant Ernst &amp; Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.</p><p><blockquote>咨询公司安永会计师事务所(Ernst&amp;Young LLP)目前预计，在全球最大的汽车市场欧洲、中国和美国，电动汽车销量将在12年内超过化石燃料燃烧器。安永使用人工智能预测工具预测，到2045年，非电动汽车销量预计将骤降至全球汽车市场的1%以下。</blockquote></p><p> Strict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.</p><p><blockquote>政府应对气候变化的严格要求正在推动欧洲和中国的需求，在这些国家，汽车制造商和消费者因销售和购买传统汽油和柴油汽车而面临越来越多的经济处罚。安永预计欧洲将引领电动化潮流，到2028年，零排放车型的销量将超过所有其他推进系统。安永预测，这一临界点将于2033年在中国到来，2036年在美国到来。</blockquote></p><p> The U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.</p><p><blockquote>美国落后于世界其他主要市场，因为唐纳德·特朗普总统执政期间放松了燃油经济性法规。自1月份上任以来，乔·拜登总统重新加入了巴黎气候协议，并提议斥资1740亿美元加速向电动汽车的转变，包括在全国安装50万个充电站。</blockquote></p><p> “The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”</p><p><blockquote>安永全球先进制造和移动出行负责人兰迪·米勒在接受采访时表示：“我们认为拜登政府的监管环境是一个很大的贡献者，因为他有雄心勃勃的目标。”“这种对美洲的影响将产生增压效应。”</blockquote></p><p> There also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.</p><p><blockquote>消费者对电动汽车的需求也在不断增长，从特斯拉公司热销的Model 3到传统汽车制造商的新型电动车型，例如通用汽车公司的电池驱动悍马卡车和福特汽车公司的F-150闪电皮卡。据咨询公司AlixPartners称，目前全球汽车制造商对电池驱动车型的投资超过2300亿美元。</blockquote></p><p> ‘More Appealing’</p><p><blockquote>“更有吸引力”</blockquote></p><p> “Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”</p><p><blockquote>“更多更具吸引力的型号正在问世，”米勒说。“你把这一点与激励因素结合起来，这些就是推动这种更乐观观点的原材料。”</blockquote></p><p> The EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.</p><p><blockquote>安永的研究还认为，现在20多岁和30多岁的千禧一代有助于推动电动汽车的采用。这些消费者在冠状病毒影响下拒绝拼车和公共交通的推动下，正在接受拥有汽车。米勒说，其中30%的人想驾驶电动汽车。</blockquote></p><p> “The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.</p><p><blockquote>米勒说：“我们看到的千禧一代的观点显然更倾向于购买电动汽车。”</blockquote></p><p> Additionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.</p><p><blockquote>此外，政府对电动汽车的购买激励措施以及城市和州对内燃机的拟议禁令相结合，正在加速电池驱动汽车的采用。</blockquote></p><p> Europe is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.</p><p><blockquote>预计到2031年，欧洲的电动汽车销量将处于领先地位，届时中国将成为全球最大的电动汽车市场。</blockquote></p><p> Vehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.</p><p><blockquote>预计到2025年，汽油和柴油动力汽车仍将占所有轻型汽车注册量的三分之二左右，但这将比五年前下降12个百分点。安永预测，到2030年，非电动汽车将占轻型汽车注册总量的一半以下。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到2033年将达到销量霸主地位，速度快于预期</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-23 07:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.</p><p><blockquote>（彭博社）——根据一项新的研究，随着更严格的法规和不断上升的兴趣推动了对零排放交通的需求，全球电动汽车将在2033年到来，比之前的预期提前了五年。</blockquote></p><p> Consultant Ernst &amp; Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.</p><p><blockquote>咨询公司安永会计师事务所(Ernst&amp;Young LLP)目前预计，在全球最大的汽车市场欧洲、中国和美国，电动汽车销量将在12年内超过化石燃料燃烧器。安永使用人工智能预测工具预测，到2045年，非电动汽车销量预计将骤降至全球汽车市场的1%以下。</blockquote></p><p> Strict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.</p><p><blockquote>政府应对气候变化的严格要求正在推动欧洲和中国的需求，在这些国家，汽车制造商和消费者因销售和购买传统汽油和柴油汽车而面临越来越多的经济处罚。安永预计欧洲将引领电动化潮流，到2028年，零排放车型的销量将超过所有其他推进系统。安永预测，这一临界点将于2033年在中国到来，2036年在美国到来。</blockquote></p><p> The U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.</p><p><blockquote>美国落后于世界其他主要市场，因为唐纳德·特朗普总统执政期间放松了燃油经济性法规。自1月份上任以来，乔·拜登总统重新加入了巴黎气候协议，并提议斥资1740亿美元加速向电动汽车的转变，包括在全国安装50万个充电站。</blockquote></p><p> “The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”</p><p><blockquote>安永全球先进制造和移动出行负责人兰迪·米勒在接受采访时表示：“我们认为拜登政府的监管环境是一个很大的贡献者，因为他有雄心勃勃的目标。”“这种对美洲的影响将产生增压效应。”</blockquote></p><p> There also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.</p><p><blockquote>消费者对电动汽车的需求也在不断增长，从特斯拉公司热销的Model 3到传统汽车制造商的新型电动车型，例如通用汽车公司的电池驱动悍马卡车和福特汽车公司的F-150闪电皮卡。据咨询公司AlixPartners称，目前全球汽车制造商对电池驱动车型的投资超过2300亿美元。</blockquote></p><p> ‘More Appealing’</p><p><blockquote>“更有吸引力”</blockquote></p><p> “Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”</p><p><blockquote>“更多更具吸引力的型号正在问世，”米勒说。“你把这一点与激励因素结合起来，这些就是推动这种更乐观观点的原材料。”</blockquote></p><p> The EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.</p><p><blockquote>安永的研究还认为，现在20多岁和30多岁的千禧一代有助于推动电动汽车的采用。这些消费者在冠状病毒影响下拒绝拼车和公共交通的推动下，正在接受拥有汽车。米勒说，其中30%的人想驾驶电动汽车。</blockquote></p><p> “The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.</p><p><blockquote>米勒说：“我们看到的千禧一代的观点显然更倾向于购买电动汽车。”</blockquote></p><p> Additionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.</p><p><blockquote>此外，政府对电动汽车的购买激励措施以及城市和州对内燃机的拟议禁令相结合，正在加速电池驱动汽车的采用。</blockquote></p><p> Europe is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.</p><p><blockquote>预计到2031年，欧洲的电动汽车销量将处于领先地位，届时中国将成为全球最大的电动汽车市场。</blockquote></p><p> Vehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.</p><p><blockquote>预计到2025年，汽油和柴油动力汽车仍将占所有轻型汽车注册量的三分之二左右，但这将比五年前下降12个百分点。安永预测，到2030年，非电动汽车将占轻型汽车注册总量的一半以下。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","NIO":"蔚来"},"source_url":"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123710128","content_text":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.\nConsultant Ernst & Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.\nStrict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.\nThe U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.\n“The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”\nThere also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.\n‘More Appealing’\n“Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”\nThe EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.\n“The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.\nAdditionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.\nEurope is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.\nVehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.","news_type":1,"symbols_score_info":{"NIO":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1248,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123597355,"gmtCreate":1624428362077,"gmtModify":1634006238208,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Yums","listText":"Yums","text":"Yums","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123597355","repostId":"1126010678","repostType":4,"repost":{"id":"1126010678","kind":"news","pubTimestamp":1624412603,"share":"https://www.laohu8.com/m/news/1126010678?lang=zh_CN&edition=full","pubTime":"2021-06-23 09:43","market":"us","language":"en","title":"Krispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转向线上，Krispy Kreme寻求6.4亿美元IPO</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1126010678","media":"Bloomberg","summary":"(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise a","content":"<p>(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering.</p><p><blockquote>（彭博）——JAB Holdings BV旗下的甜甜圈连锁店Krispy Kreme Inc.正寻求通过首次公开募股筹集高达6.4亿美元的资金。</blockquote></p><p> The company said in a filing Tuesday that it plans to sell almost 27 million shares for $21 to $24 apiece. At the top end of the range, Krispy Kreme would have a market value of $3.86 billion based on the outstanding shares listed in the filing with the U.S. Securities and Exchange Commission.</p><p><blockquote>该公司在周二提交的文件中表示，计划以每股21至24美元的价格出售近2700万股股票。根据向美国证券交易委员会提交的文件中列出的已发行股票，Krispy Kreme的市值将达到38.6亿美元。</blockquote></p><p> Amid photos of doughnuts dripping with sugary glaze and dotted with sprinkles, the company declares in the filing that its purpose is “to touch and enhance lives through the joy of Krispy Kreme.”</p><p><blockquote>在甜甜圈滴着糖釉并点缀着糖屑的照片中，该公司在文件中宣称，其目的是“通过Krispy Kreme的快乐来感动和改善生活”。</blockquote></p><p> Since its acquisition by Luxembourg-based conglomerate JAB in 2016, Krispy Kreme has expanded its online presence. Its e-commerce business now accounts for close to a fifth of sales in the U.S., fueled by its Insomnia Cookies delivery concept.</p><p><blockquote>自2016年被卢森堡企业集团JAB收购以来，Krispy Kreme扩大了其在线业务。在失眠饼干配送概念的推动下，其电子商务业务目前占美国销售额的近五分之一。</blockquote></p><p> Net revenue for the Charlotte, North Carolina-based chain rose 23% to $322 million in the quarter ended April 4, according to the filing. Its net loss for the quarter shrunk from $11 million in 2020 to $378,000 this year.</p><p><blockquote>文件显示，截至4月4日的季度，这家总部位于北卡罗来纳州夏洛特的连锁店的净收入增长了23%，达到3.22亿美元。该季度净亏损从2020年的1100万美元缩小至今年的37.8万美元。</blockquote></p><p> Krispy Kreme plans to use proceeds from the IPO to pay down debt and buy back shares from certain executives, as well as for general corporate purposes, according to the filing. JAB will continue to own almost 78% of the company’s shares after the IPO.</p><p><blockquote>文件显示，Krispy Kreme计划将IPO所得用于偿还债务、从某些高管手中回购股票以及用于一般公司用途。IPO后，JAB将继续持有该公司近78%的股份。</blockquote></p><p> The offering is being led by JPMorgan Chase &amp; Co., Morgan Stanley, Bank of America Corp. and Citigroup Inc. The company plans to list on the Nasdaq Global Select Market under the symbol DNUT.</p><p><blockquote>此次发行由摩根大通、摩根士丹利、美国银行和花旗集团牵头。该公司计划在纳斯达克全球精选市场上市，代码为DNUT。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Krispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转向线上，Krispy Kreme寻求6.4亿美元IPO</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKrispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转向线上，Krispy Kreme寻求6.4亿美元IPO</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-23 09:43</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering.</p><p><blockquote>（彭博）——JAB Holdings BV旗下的甜甜圈连锁店Krispy Kreme Inc.正寻求通过首次公开募股筹集高达6.4亿美元的资金。</blockquote></p><p> The company said in a filing Tuesday that it plans to sell almost 27 million shares for $21 to $24 apiece. At the top end of the range, Krispy Kreme would have a market value of $3.86 billion based on the outstanding shares listed in the filing with the U.S. Securities and Exchange Commission.</p><p><blockquote>该公司在周二提交的文件中表示，计划以每股21至24美元的价格出售近2700万股股票。根据向美国证券交易委员会提交的文件中列出的已发行股票，Krispy Kreme的市值将达到38.6亿美元。</blockquote></p><p> Amid photos of doughnuts dripping with sugary glaze and dotted with sprinkles, the company declares in the filing that its purpose is “to touch and enhance lives through the joy of Krispy Kreme.”</p><p><blockquote>在甜甜圈滴着糖釉并点缀着糖屑的照片中，该公司在文件中宣称，其目的是“通过Krispy Kreme的快乐来感动和改善生活”。</blockquote></p><p> Since its acquisition by Luxembourg-based conglomerate JAB in 2016, Krispy Kreme has expanded its online presence. Its e-commerce business now accounts for close to a fifth of sales in the U.S., fueled by its Insomnia Cookies delivery concept.</p><p><blockquote>自2016年被卢森堡企业集团JAB收购以来，Krispy Kreme扩大了其在线业务。在失眠饼干配送概念的推动下，其电子商务业务目前占美国销售额的近五分之一。</blockquote></p><p> Net revenue for the Charlotte, North Carolina-based chain rose 23% to $322 million in the quarter ended April 4, according to the filing. Its net loss for the quarter shrunk from $11 million in 2020 to $378,000 this year.</p><p><blockquote>文件显示，截至4月4日的季度，这家总部位于北卡罗来纳州夏洛特的连锁店的净收入增长了23%，达到3.22亿美元。该季度净亏损从2020年的1100万美元缩小至今年的37.8万美元。</blockquote></p><p> Krispy Kreme plans to use proceeds from the IPO to pay down debt and buy back shares from certain executives, as well as for general corporate purposes, according to the filing. JAB will continue to own almost 78% of the company’s shares after the IPO.</p><p><blockquote>文件显示，Krispy Kreme计划将IPO所得用于偿还债务、从某些高管手中回购股票以及用于一般公司用途。IPO后，JAB将继续持有该公司近78%的股份。</blockquote></p><p> The offering is being led by JPMorgan Chase &amp; Co., Morgan Stanley, Bank of America Corp. and Citigroup Inc. The company plans to list on the Nasdaq Global Select Market under the symbol DNUT.</p><p><blockquote>此次发行由摩根大通、摩根士丹利、美国银行和花旗集团牵头。该公司计划在纳斯达克全球精选市场上市，代码为DNUT。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DNUT":"Krispy Kreme, Inc."},"source_url":"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126010678","content_text":"(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering.\nThe company said in a filing Tuesday that it plans to sell almost 27 million shares for $21 to $24 apiece. At the top end of the range, Krispy Kreme would have a market value of $3.86 billion based on the outstanding shares listed in the filing with the U.S. Securities and Exchange Commission.\nAmid photos of doughnuts dripping with sugary glaze and dotted with sprinkles, the company declares in the filing that its purpose is “to touch and enhance lives through the joy of Krispy Kreme.”\nSince its acquisition by Luxembourg-based conglomerate JAB in 2016, Krispy Kreme has expanded its online presence. Its e-commerce business now accounts for close to a fifth of sales in the U.S., fueled by its Insomnia Cookies delivery concept.\nNet revenue for the Charlotte, North Carolina-based chain rose 23% to $322 million in the quarter ended April 4, according to the filing. Its net loss for the quarter shrunk from $11 million in 2020 to $378,000 this year.\nKrispy Kreme plans to use proceeds from the IPO to pay down debt and buy back shares from certain executives, as well as for general corporate purposes, according to the filing. JAB will continue to own almost 78% of the company’s shares after the IPO.\nThe offering is being led by JPMorgan Chase & Co., Morgan Stanley, Bank of America Corp. and Citigroup Inc. The company plans to list on the Nasdaq Global Select Market under the symbol DNUT.","news_type":1,"symbols_score_info":{"DNUT":0.9}},"isVote":1,"tweetType":1,"viewCount":3183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123594843,"gmtCreate":1624428337982,"gmtModify":1634006238572,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123594843","repostId":"2145057786","repostType":4,"isVote":1,"tweetType":1,"viewCount":2992,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123595713,"gmtCreate":1624428311132,"gmtModify":1634006238814,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123595713","repostId":"2145066250","repostType":4,"isVote":1,"tweetType":1,"viewCount":2502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123592750,"gmtCreate":1624428287070,"gmtModify":1634006239664,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123592750","repostId":"1192380860","repostType":4,"isVote":1,"tweetType":1,"viewCount":1561,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123592828,"gmtCreate":1624428233064,"gmtModify":1634006240151,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123592828","repostId":"1174011543","repostType":4,"repost":{"id":"1174011543","kind":"news","pubTimestamp":1624425845,"share":"https://www.laohu8.com/m/news/1174011543?lang=zh_CN&edition=full","pubTime":"2021-06-23 13:24","market":"us","language":"en","title":"FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管一些员工表示担忧，FDA还是批准了百健(Biogen)的阿尔茨海默病药物</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174011543","media":"WSJ","summary":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the obje","content":"<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.</p><p><blockquote>美国。根据最新发布的内部备忘录，美国食品和药物管理局不顾该机构统计学家的反对，批准了十年来第一种新的阿尔茨海默氏症药物，他们表示没有足够的证据支持批准。</blockquote></p><p> In the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.</p><p><blockquote>在周二发布的内部备忘录中，FDA官员讨论了是否批准BiogenInc.BIIB-1.71%的药物，尽管该机构药物统计办公室提出了反对意见，该办公室表示，临床试验数据达不到将新产品投放市场通常所需的证据。</blockquote></p><p> Ultimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.</p><p><blockquote>备忘录显示，最终，高级官员认为，表明该药物有效的证据虽然尚无定论，但足以让医生和患者自行决定是否服用。</blockquote></p><p> “FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”</p><p><blockquote>FDA新药办公室主任Peter Stein在一份备忘录中写道：“那么，FDA面临的情况是，临床终点的现有证据不足以达到我们标准批准aducanumab所需的证据。”他对批准的支持。“与此同时，[阿尔茨海默氏症]患者患有严重、进行性、最终致命的疾病，并且迫切需要治疗。”</blockquote></p><p> The FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.</p><p><blockquote>FDA公开了其内部审议情况，因为它面临一些医生和科学家对6月7日批准这种名为Aduhelm的药物的批评。</blockquote></p><p> The critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.</p><p><blockquote>批评者表示，FDA忽视了通常要求制药商遵守的科学标准，可能会促使联邦政府在一种可能不起作用的药物上花费数十亿美元。</blockquote></p><p> “While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”</p><p><blockquote>“虽然我完全支持该中心最近批准该疗法的决定，但我承认对这一决定存在不同意见，包括FDA内部，并且围绕我们的审查流程和我们考虑支持该疗法的数据可能会继续存在问题FDA代理专员珍妮特·伍德库克(Janet Woodcock)表示。“最终，FDA一组经验丰富的医学审查人员得出结论，有足够的证据通过加速批准途径批准阿尔茨海默病疗法。”</blockquote></p><p> Supporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.</p><p><blockquote>支持者表示，FDA的决定为缺乏任何有望减缓阿尔茨海默氏症进展的药物的患者提供了生命线，并且该决定可能会刺激更多、更好药物的开发。</blockquote></p><p> The agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.</p><p><blockquote>该机构通常会在做出决定后发布批准文件，尽管通常不会像这次那么快。83页的备忘录似乎是FDA审议的一部分，很大程度上反映了高级官员的交流。</blockquote></p><p> Tristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.</p><p><blockquote>一份内部文件显示，FDA生物统计学审查员Tristan Massie“不同意所有数据提供了足够的证据来支持aducanumab在阿尔茨海默病中的疗效，也不建议批准”。</blockquote></p><p> Patrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”</p><p><blockquote>FDA最高级别的药物评估官员帕特里齐亚·卡瓦佐尼(Patrizia Cavazzoni)在另一份备忘录中写道，该机构的药物生物统计办公室“为其建议提供了文件，即申请中没有提供实质性的有效性证据”。</blockquote></p><p> That office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.</p><p><blockquote>该办公室的完整反对分析并未包含在周二提供的材料中，但其中部分内容包含在内。</blockquote></p><p> Despite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.</p><p><blockquote>尽管遭到反对，卡瓦佐尼博士写道，百健已经满足了“加速批准”的要求，这是一种监管许可，即使药物满足了未满足的需求，其临床益处仍存在不确定性，也可以上市。严重疾病并对疾病的生物标志有影响。</blockquote></p><p> Dr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”</p><p><blockquote>Cavazzoni博士写道，Aduhelm符合这一标准，因为它可以减少一种称为淀粉样蛋白的粘性物质，这种物质“很可能预测临床益处”。</blockquote></p><p> Some doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.</p><p><blockquote>一些医生和科学家表示，针对淀粉样蛋白斑块尚未被证明可以减缓阿尔茨海默氏症。建议FDA拒绝该药物的顾问小组的一些成员以该机构的批准为由退出了该委员会。</blockquote></p><p> Biogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.</p><p><blockquote>Biogen列出的Aduhelm价格为每年56,000美元，患者和医疗保险也可能面临检测费用。</blockquote></p><p> About six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.</p><p><blockquote>大约600万美国人患有阿尔茨海默氏症，这是一种渐进性疾病，会剥夺人们的记忆和认知能力。Biogen表示，其中多达200万人可能会从该药物中受益。</blockquote></p><p> The FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.</p><p><blockquote>FDA的批准导致百健(Biogen)的股价飙升。该公司表示，预计今年该药物的收入很少，部分原因是管理该药物的后勤挑战，但明年销售额将开始增加。</blockquote></p><p> Analysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.</p><p><blockquote>FactSet的数据显示，分析师预计2022年销售额为9.463亿美元。预计2026年销售额将增长至52亿美元。</blockquote></p><p> The memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.</p><p><blockquote>备忘录显示，FDA官员试图平衡Aduhelm低于标准的研究数据与阿尔茨海默病患者及其家人尝试任何可能有帮助的新治疗方法的愿望。</blockquote></p><p></p><p> “There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.</p><p><blockquote>斯坦博士写道：“临床益处仍然存在不确定性。”但他写道，如果FDA等待该公司完成另一项临床研究，“任何批准都将在延迟多年后获得”，患者“可能会遭受不可逆转的脑神经元、认知功能和记忆丧失”。</blockquote></p><p> The FDA said it plans to release more documents regarding its decision making as early as next week.</p><p><blockquote>FDA表示，计划最早在下周发布更多有关其决策的文件。</blockquote></p><p> The FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.</p><p><blockquote>FDA的批准主要基于Biogen启动的两项大型3期临床试验，以证明其药物有助于减缓早期阿尔茨海默氏症患者的认知能力下降。</blockquote></p><p> In March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.</p><p><blockquote>2019年3月，在独立监测委员会得出该药物不太可能帮助患者后，该公司提前停止了研究。</blockquote></p><p> Seven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.</p><p><blockquote>然而，七个月后，该公司做出了令人惊讶的逆转，并表示在对研究停止后获得的试验数据进行额外分析后，现在计划寻求FDA的批准。该公司表示，其分析发现该药物在一项研究中成功，但在第二项研究中失败。</blockquote></p><p> The FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.</p><p><blockquote>FDA备忘录提供了一些关于Biogen大转变的新细节。根据一份“摘要备忘录”文件，2019年6月，该公司会见了FDA官员，双方一致认为这些研究不应停止。</blockquote></p><p> At the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.</p><p><blockquote>在会议上，FDA官员建议Biogen进一步分析这些研究，以了解尽管试验停止且结果相互矛盾，但是否仍有可能从数据中得出结论。</blockquote></p><p> Several months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.</p><p><blockquote>备忘录称，几个月后，即2019年10月，该机构和公司再次会面，并同意这些研究仍可用于评估该药物的有效性。</blockquote></p><p> The following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.</p><p><blockquote>第二天，即10月22日，百健(Biogen)宣布将寻求该药物的批准，这推高了其股价，使其市值增加了数十亿美元。</blockquote></p><p> The company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.</p><p><blockquote>百健(Biogen)首席执行官米歇尔·沃纳索斯(Michel Vounatsos)当时在接受采访时表示，该公司几个月来一直在悄悄重新审查这些数据，但直到最近一次与FDA官员会面时才有信心向前推进。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管一些员工表示担忧，FDA还是批准了百健(Biogen)的阿尔茨海默病药物</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管一些员工表示担忧，FDA还是批准了百健(Biogen)的阿尔茨海默病药物</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">WSJ</strong><span class=\"h-time small\">2021-06-23 13:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.</p><p><blockquote>美国。根据最新发布的内部备忘录，美国食品和药物管理局不顾该机构统计学家的反对，批准了十年来第一种新的阿尔茨海默氏症药物，他们表示没有足够的证据支持批准。</blockquote></p><p> In the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.</p><p><blockquote>在周二发布的内部备忘录中，FDA官员讨论了是否批准BiogenInc.BIIB-1.71%的药物，尽管该机构药物统计办公室提出了反对意见，该办公室表示，临床试验数据达不到将新产品投放市场通常所需的证据。</blockquote></p><p> Ultimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.</p><p><blockquote>备忘录显示，最终，高级官员认为，表明该药物有效的证据虽然尚无定论，但足以让医生和患者自行决定是否服用。</blockquote></p><p> “FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”</p><p><blockquote>FDA新药办公室主任Peter Stein在一份备忘录中写道：“那么，FDA面临的情况是，临床终点的现有证据不足以达到我们标准批准aducanumab所需的证据。”他对批准的支持。“与此同时，[阿尔茨海默氏症]患者患有严重、进行性、最终致命的疾病，并且迫切需要治疗。”</blockquote></p><p> The FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.</p><p><blockquote>FDA公开了其内部审议情况，因为它面临一些医生和科学家对6月7日批准这种名为Aduhelm的药物的批评。</blockquote></p><p> The critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.</p><p><blockquote>批评者表示，FDA忽视了通常要求制药商遵守的科学标准，可能会促使联邦政府在一种可能不起作用的药物上花费数十亿美元。</blockquote></p><p> “While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”</p><p><blockquote>“虽然我完全支持该中心最近批准该疗法的决定，但我承认对这一决定存在不同意见，包括FDA内部，并且围绕我们的审查流程和我们考虑支持该疗法的数据可能会继续存在问题FDA代理专员珍妮特·伍德库克(Janet Woodcock)表示。“最终，FDA一组经验丰富的医学审查人员得出结论，有足够的证据通过加速批准途径批准阿尔茨海默病疗法。”</blockquote></p><p> Supporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.</p><p><blockquote>支持者表示，FDA的决定为缺乏任何有望减缓阿尔茨海默氏症进展的药物的患者提供了生命线，并且该决定可能会刺激更多、更好药物的开发。</blockquote></p><p> The agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.</p><p><blockquote>该机构通常会在做出决定后发布批准文件，尽管通常不会像这次那么快。83页的备忘录似乎是FDA审议的一部分，很大程度上反映了高级官员的交流。</blockquote></p><p> Tristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.</p><p><blockquote>一份内部文件显示，FDA生物统计学审查员Tristan Massie“不同意所有数据提供了足够的证据来支持aducanumab在阿尔茨海默病中的疗效，也不建议批准”。</blockquote></p><p> Patrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”</p><p><blockquote>FDA最高级别的药物评估官员帕特里齐亚·卡瓦佐尼(Patrizia Cavazzoni)在另一份备忘录中写道，该机构的药物生物统计办公室“为其建议提供了文件，即申请中没有提供实质性的有效性证据”。</blockquote></p><p> That office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.</p><p><blockquote>该办公室的完整反对分析并未包含在周二提供的材料中，但其中部分内容包含在内。</blockquote></p><p> Despite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.</p><p><blockquote>尽管遭到反对，卡瓦佐尼博士写道，百健已经满足了“加速批准”的要求，这是一种监管许可，即使药物满足了未满足的需求，其临床益处仍存在不确定性，也可以上市。严重疾病并对疾病的生物标志有影响。</blockquote></p><p> Dr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”</p><p><blockquote>Cavazzoni博士写道，Aduhelm符合这一标准，因为它可以减少一种称为淀粉样蛋白的粘性物质，这种物质“很可能预测临床益处”。</blockquote></p><p> Some doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.</p><p><blockquote>一些医生和科学家表示，针对淀粉样蛋白斑块尚未被证明可以减缓阿尔茨海默氏症。建议FDA拒绝该药物的顾问小组的一些成员以该机构的批准为由退出了该委员会。</blockquote></p><p> Biogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.</p><p><blockquote>Biogen列出的Aduhelm价格为每年56,000美元，患者和医疗保险也可能面临检测费用。</blockquote></p><p> About six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.</p><p><blockquote>大约600万美国人患有阿尔茨海默氏症，这是一种渐进性疾病，会剥夺人们的记忆和认知能力。Biogen表示，其中多达200万人可能会从该药物中受益。</blockquote></p><p> The FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.</p><p><blockquote>FDA的批准导致百健(Biogen)的股价飙升。该公司表示，预计今年该药物的收入很少，部分原因是管理该药物的后勤挑战，但明年销售额将开始增加。</blockquote></p><p> Analysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.</p><p><blockquote>FactSet的数据显示，分析师预计2022年销售额为9.463亿美元。预计2026年销售额将增长至52亿美元。</blockquote></p><p> The memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.</p><p><blockquote>备忘录显示，FDA官员试图平衡Aduhelm低于标准的研究数据与阿尔茨海默病患者及其家人尝试任何可能有帮助的新治疗方法的愿望。</blockquote></p><p></p><p> “There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.</p><p><blockquote>斯坦博士写道：“临床益处仍然存在不确定性。”但他写道，如果FDA等待该公司完成另一项临床研究，“任何批准都将在延迟多年后获得”，患者“可能会遭受不可逆转的脑神经元、认知功能和记忆丧失”。</blockquote></p><p> The FDA said it plans to release more documents regarding its decision making as early as next week.</p><p><blockquote>FDA表示，计划最早在下周发布更多有关其决策的文件。</blockquote></p><p> The FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.</p><p><blockquote>FDA的批准主要基于Biogen启动的两项大型3期临床试验，以证明其药物有助于减缓早期阿尔茨海默氏症患者的认知能力下降。</blockquote></p><p> In March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.</p><p><blockquote>2019年3月，在独立监测委员会得出该药物不太可能帮助患者后，该公司提前停止了研究。</blockquote></p><p> Seven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.</p><p><blockquote>然而，七个月后，该公司做出了令人惊讶的逆转，并表示在对研究停止后获得的试验数据进行额外分析后，现在计划寻求FDA的批准。该公司表示，其分析发现该药物在一项研究中成功，但在第二项研究中失败。</blockquote></p><p> The FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.</p><p><blockquote>FDA备忘录提供了一些关于Biogen大转变的新细节。根据一份“摘要备忘录”文件，2019年6月，该公司会见了FDA官员，双方一致认为这些研究不应停止。</blockquote></p><p> At the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.</p><p><blockquote>在会议上，FDA官员建议Biogen进一步分析这些研究，以了解尽管试验停止且结果相互矛盾，但是否仍有可能从数据中得出结论。</blockquote></p><p> Several months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.</p><p><blockquote>备忘录称，几个月后，即2019年10月，该机构和公司再次会面，并同意这些研究仍可用于评估该药物的有效性。</blockquote></p><p> The following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.</p><p><blockquote>第二天，即10月22日，百健(Biogen)宣布将寻求该药物的批准，这推高了其股价，使其市值增加了数十亿美元。</blockquote></p><p> The company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.</p><p><blockquote>百健(Biogen)首席执行官米歇尔·沃纳索斯(Michel Vounatsos)当时在接受采访时表示，该公司几个月来一直在悄悄重新审查这些数据，但直到最近一次与FDA官员会面时才有信心向前推进。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2\">WSJ</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174011543","content_text":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.\nIn the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.\nUltimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.\n“FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”\nThe FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.\nThe critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.\n“While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”\nSupporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.\nThe agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.\nTristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.\nPatrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”\nThat office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.\nDespite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.\nDr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”\nSome doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.\nBiogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.\nAbout six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.\nThe FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.\nAnalysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.\nThe memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.\n“There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.\nThe FDA said it plans to release more documents regarding its decision making as early as next week.\nThe FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.\nIn March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.\nSeven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.\nThe FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.\nAt the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.\nSeveral months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.\nThe following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.\nThe company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":2865,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}